PTCT PTC Therapeutics Inc.

50.69
-1.24  -2%
Previous Close 51.92
Open 50.9
Price To Book 4.71
Market Cap 3,123,766,171
Shares 61,630,979
Volume 468,631
Short Ratio
Av. Daily Volume 750,139
Stock charts supplied by TradingView

NewsSee all news

  1. Risdiplam (RG7916) Pivotal FIREFISH Study Demonstrated Statistically Significant Improvement in Infants with Type 1 Spinal Muscular Atrophy

    SOUTH PLAINFIELD, N.J., Jan. 23, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced positive topline results from part 2 of FIREFISH demonstrating that the study met its primary endpoint of

  2. PTC Therapeutics Provides Corporate Update and Highlights Pipeline Progress at 2020 J.P. Morgan Healthcare Conference

    SOUTH PLAINFIELD, N.J., Jan. 13, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today is providing a corporate update that will be presented at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday,

  3. PTC Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

    SOUTH PLAINFIELD, N.J., Jan. 6, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that management will present a company update at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday,

  4. PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SOUTH PLAINFIELD, N.J., Dec. 13, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that on December 9, 2019 it approved non-statutory stock options to purchase an aggregate of 59,150 shares of its

  5. PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SOUTH PLAINFIELD, N.J., Nov. 29, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that on November 25, 2019 it approved non-statutory stock options to purchase an aggregate of 144,550 shares of

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data met primary endpoint - November 11, 2019. Data to be presented at the International Scientific Congress on Spinal Muscular Atrophy. CC on February 6, 2020 at 9am EST.
Risdiplam - SUNFISH
Spinal Muscular Atrophy (SMA)
Received a Refusal to File letter February 23 2016. Appeal rejected October 17, 2016. Decision made to resubmit NDA during 1Q 2017 under protest. Further CRL October 25, 2017. NDA to be refiled 2020.
Translarna
Duchenne muscular dystrophy caused by nonsense mutations (nmDMD)
FDA Approval announced October 5, 2018,
Inotersen (IONIS-TTRRx)
NEURO-TTR - familial amyloid polyneuropathy (FAP).
Phase 3 data released March 2, 2017 - endpoints not met. Development to be discontinued.
Translarna
Nonsense mutation cystic fibrosis
PDUFA date May 24, 2020 under priority review. Top-line results from the pivotal portion of the open label FIREFISH trial are due 1Q 2020.
Risdiplam (RG7916)
Spinal Muscular Atrophy (SMA) Type 1
BLA filing due 2Q 2020.
GT-AADC
AADC deficiency
Phase 1 enrolment to be completed by the end of 2019.
PTC596
Leiomyosarcoma (LMS)
Phase 1 enrolment to be completed by the end of 2019.
PTC596
Diffuse Intrinsic Pontine Glioma (DIPG)
Phase 1 enrolment to be completed by the end of 2019.
PTC299
Acute myeloid leukemia (AML)
FDA Approval announced for label expansion June 7, 2019.
Emflaza
Duchenne muscular dystrophy (age 2-5)

Latest News

  1. Risdiplam (RG7916) Pivotal FIREFISH Study Demonstrated Statistically Significant Improvement in Infants with Type 1 Spinal Muscular Atrophy

    SOUTH PLAINFIELD, N.J., Jan. 23, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced positive topline results from part 2 of FIREFISH demonstrating that the study met its primary endpoint of

  2. PTC Therapeutics Provides Corporate Update and Highlights Pipeline Progress at 2020 J.P. Morgan Healthcare Conference

    SOUTH PLAINFIELD, N.J., Jan. 13, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today is providing a corporate update that will be presented at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday,

  3. PTC Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

    SOUTH PLAINFIELD, N.J., Jan. 6, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that management will present a company update at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday,

  4. PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SOUTH PLAINFIELD, N.J., Dec. 13, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that on December 9, 2019 it approved non-statutory stock options to purchase an aggregate of 59,150 shares of its

  5. PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SOUTH PLAINFIELD, N.J., Nov. 29, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that on November 25, 2019 it approved non-statutory stock options to purchase an aggregate of 144,550 shares of

  6. PTC Therapeutics Announces FDA Grants Priority Review to Risdiplam for the Treatment of Spinal Muscular Atrophy

    SOUTH PLAINFIELD, N.J., Nov. 25, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that the United States Food and Drug Administration (FDA) has granted priority review for the New Drug

  7. PTC Therapeutics to Present at the Evercore ISI 2nd Annual HealthCONx Conference

    SOUTH PLAINFIELD, N.J., Nov. 19, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that management will participate in a panel discussion titled, "Gene Therapy with Base Business – Extracting

  8. PTC Therapeutics Launches A No-Cost Testing Program to Drive AADC Deficiency Patient Identification

    SOUTH PLAINFIELD, N.J., Nov. 18, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced the launch of a no-cost testing program for aromatic L-amino acid decarboxylase (AADC) deficiency, a rare genetic

  9. Intrexon Reports Third Quarter 2019 Financial Results

    GERMANTOWN, Md., Nov. 12, 2019 /PRNewswire/ -- Intrexon Corporation (NASDAQ:XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced its

  10. Risdiplam (RG7916) Pivotal SUNFISH Study Demonstrates Statistically Significant Improvement for Patients with Type 2/3 Spinal Muscular Atrophy

    SOUTH PLAINFIELD, N.J., Nov. 11, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced positive results from part 2 of SUNFISH demonstrating that the study met its primary endpoint of change from

  11. PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SOUTH PLAINFIELD, N.J., Oct. 31, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that on October 25, 2019 it approved non-statutory stock options to purchase an aggregate of 339,875 shares of

  12. PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SOUTH PLAINFIELD, N.J., Oct. 23, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that on October 18, 2019 it approved non-statutory stock options to purchase an aggregate of 144,150 shares of

  13. PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2019 Financial Results

    SOUTH PLAINFIELD, N.J., Oct. 15, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that the Company will host a webcast conference call to report its third quarter 2019 financial results

  14. PTC Therapeutics Establishes Strategic Collaboration with Aldevron to Support GMP Plasmid Manufacturing

    SOUTH PLAINFIELD, N.J., Oct. 7, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced a collaboration with Aldevron, LLC to secure GMP manufacturing capacity for PTC's gene therapy portfolio,

  15. PTC Therapeutics Announces New Real-World Analysis Demonstrating Translarna™ (ataluren) Slows Disease Progression in Patients with Duchenne Muscular Dystrophy

    SOUTH PLAINFIELD, N.J., Oct. 4, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that data from STRIDE,* the first international registry for patients with Duchenne muscular dystrophy due to a

  16. Risdiplam Spinal Muscular Atrophy Data Demonstrating Continued Benefit Presented at World Muscle Society Congress

    SOUTH PLAINFIELD, N.J., Oct. 2, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced data demonstrating the ongoing benefit of risdiplam (RG7916) for the treatment of all types of spinal muscular

  17. PTC Therapeutics to Participate at Upcoming Investor Conferences

    SOUTH PLAINFIELD, N.J., Sept. 27, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that management will present a company update at the following conferences: Cantor Global Healthcare

  18. PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SOUTH PLAINFIELD, N.J., Sept. 20, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that on September 18, 2019 it approved non-statutory stock options to purchase an aggregate of 211,500 shares of

  19. PTC Therapeutics Announces Pricing of Private Offering of Convertible Senior Notes

    SOUTH PLAINFIELD, N.J., Sept. 18, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today that it has priced its private offering of $250.0 million aggregate principal amount of its convertible senior

  20. PTC Therapeutics Announces Pricing of Public Offering of Common Stock

    SOUTH PLAINFIELD, N.J., Sept. 18, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today the pricing of a public offering of 2,475,248 shares of its common stock at a public offering price of $40.40

  21. PTC Therapeutics Announces Proposed Public Offering of Common Stock

    SOUTH PLAINFIELD, N.J., Sept. 17, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today that it is commencing a public offering of $100.0 million of shares of its common stock. PTC intends to grant

  22. PTC Therapeutics Announces Proposed Private Offering of Convertible Senior Notes

    SOUTH PLAINFIELD, N.J., Sept. 17, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today that it is commencing an offering of $250.0 million aggregate principal amount of its convertible senior notes

  23. PTC Therapeutics Celebrates the Fifth Anniversary of STRIVE Grant Awards by Announcing 2019 Award Winners

    SOUTH PLAINFIELD, N.J., Sept. 6, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) is pleased to announce the recipients of the Company's 2019 global STRIVE Awards program, designed to support non-profit